Ledipasvir–sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial

The Lancet Gastroenterology and Hepatology

Volumn 2, Issue 5, 2017, Pages 347-353

  Rockstroh, Jürgen K ^a   Bhagani, Sanjay ^b   Hyland, Robert H ^c   Yun, Chohee ^c   Dvory Sobol, Hadas ^c   Zheng, Wei ^c   Brainard, Diana M ^c   Ingiliz, Patrick ^d   Lutz, Thomas ^e   Boesecke, Christoph ^a   Nelson, Mark ^f  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c GILEAD SCIENCES   (United States)

^d Center for Infectiology (CIB)   (Germany)

^e Infektiologikum   (Germany)

^f CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; SOFOSBUVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ACUTE HEPATITIS C; ADULT; ARTICLE; DIARRHEA; FATIGUE; HEADACHE; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MALE; MIXED INFECTION; NAUSEA; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHINOPHARYNGITIS; THROMBOPHLEBITIS; ACUTE DISEASE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; MIDDLE AGED; PILOT STUDY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ACUTE DISEASE; ADULT; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; COINFECTION; DRUG ADMINISTRATION SCHEDULE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; VIRAL LOAD;

EID: 85017270809     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(17)30003-1     Document Type: Article

References (21)

1. 1 Jaeckel, E, Cornberg, M, Wedemeyer, H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 345 (2001), 1452–1457.
2. 2 Deterding, K, Grüner, N, Buggisch, P, et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis 13 (2013), 497–506.
3. 3 Ghosn, J, Pierre-François, S, Thibault, V, et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med 5 (2004), 303–306.
4. 4 Danta, M, Brown, D, Bhagani, S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 21 (2007), 983–991.
5. 5 Doyle, JS, Deterding, K, Grebely, J, et al. Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. J Viral Hepat 22 (2015), 1020–1032.
6. 6 Boesecke, C, Ingiliz, P, Reiberger, T, et al. Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome. Infection 44 (2016), 93–101.
7. 7 Santantonio, T, Fasano, M, Sagnelli, E, et al. Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin. Hepatology 59 (2014), 2101–2109.
8. 8 European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 20 (2011), 399–409.
9. 9 Boesecke C, Nelson M, Ingiliz P, et al. Does the availability of new DAAs influence treatment uptake in acute hepatitis C in HIV coinfection? 22nd Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 23–26, 2015.
10. 10 Martinello, M, Gane, E, Hellard, M, et al. Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: the DARE-C II study. Hepatology 64 (2016), 1911–1921.
11. 11 Deterding, K, Spinner, CD, Schott, E, et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis 17 (2017), 215–222.
12. 12 European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66 (2016), 153–194.
13. 13 Midgard, H, Weir, A, Palmateer, N, et al. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol 65 (2016), S33–S45.
14. 14 Ingiliz, P, Martin, TC, Rodger, A, et al., NEAT study group. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol, 2016, 10.1016/j.jhep.2016.09.004 published online Sept 17.
15. 15 Kowdley, KV, Gordon, SC, Reddy, KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370 (2014), 1879–1888.
16. 16 Poordad F, Lawitz E, Gutierrez JA, et al. C-SWIFT: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks. 2015 International Liver Congress: 50th Annual Meeting of the European Association for the Study of the Liver; Vienna, Austria; April 22–26, 2015.
17. 17 Gane E, Nguyen M, Kwo P, et al. Short-duration treatment with sofosbuvir/velpatasvir plus GS-9857 in treatment-naïve genotype 1–6 HCV-infected patients with or without cirrhosis. 2016 International Liver Congress: 51st Annual Meeting of the European Association for the Study of the Liver; Barcelona, Spain; April 13–17, 2016.
18. 18 Rehermann, B, Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 19 (2013), 859–868.
19. 19 Naggie S, Marks KM, Hughes M, et al. Sofosbuvir plus ribavirin without interferon for treatment of acute hepatitis C virus infection in HIV-1 infected Individuals (SWIFT-C). 66th Annual Meeting of the American Association for the Study of Liver diseases; San Francisco, CA, USA; Nov 13–17, 2015.
20. 20 Martinello M, Gane EJ, Hellard M, et al. Sofosbuvir and ribavirin for six weeks is not effective among people with acute and recently acquired HCV infection: the DARE-C II Study. 66th Annual Meeting of the American Association for the Study of Liver diseases; San Francisco, CA, USA; Nov 7–11, 2015.
21. 21 Basu P, Shah N, John N, et al. Sofosbuvir and ledipasvir versus sofosbuvir and simeprevir combination therapy in the management of acute hepatitis C: a randomized open label prospective clinical pilot study. SLAM C study. Interim data. 66th Annual Meeting of the American Association for the Study of Liver diseases; San Francisco, CA, USA; Nov 13–17, 2015.